Abstract
In clinical studies GS-US-380-1489 (study 1489) and GS-US-380-1490 (study 1490), bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF), dolutegravir-abacavir-lamivudine (DTG-ABC-3TC), and dolutegravir plus emtricitabine-tenofovir alafenamide (DTG+F-TAF) treatment achieved high rates of virologic suppression in HIV-1 treatment-naive participants through week 48. Preexisting primary drug resistance was present at levels of 1.3% integrase strand transfer inhibitor resistance (INSTI-R), 2.7% nucleoside reverse transcriptase inhibitor resistance (NRTI-R), 14.1% nonnucleoside reverse transcriptase inhibitor resistance (NNRTI-R), and 3.5% protease inhibitor resistance (PI-R) in the 1,274 participants from these studies. These mutations did not affect treatment outcomes. Resistance analyses in 13 virologic failures found no emergent resistance to study drugs.
References
Jan 10, 2003·Nucleic Acids Research·Soo-Yon RheeRobert W Shafer
Feb 9, 2008·HIV Medicine·J K RockstrohUNKNOWN EACS Executive Committee
Jul 4, 2008·Journal of Virology·Richard E Myers, Deenan Pillay
Mar 7, 2009·PloS One·Diane E BennettRobert W Shafer
Aug 20, 2009·PloS One·Zabrina L BrummeSimon Mallal
Oct 22, 2010·AIDS Research and Human Retroviruses·Vici VargheseRobert W Shafer
Nov 19, 2010·American Journal of Epidemiology·Gwenn MenvielleH Bas Bueno-de-Mesquita
Jan 12, 2013·Lancet·Francois RaffiUNKNOWN SPRING-2 Study Group
Jul 9, 2013·Lancet·Pedro CahnUNKNOWN extended SAILING Study Team
Oct 23, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christopher B HurtJoseph J Eron
Nov 8, 2013·The New England Journal of Medicine·Sharon L WalmsleyUNKNOWN SINGLE Investigators
Apr 5, 2014·Lancet·Bonaventura ClotetUNKNOWN ING114915 Study Team
Dec 11, 2014·AIDS·Quang D PhamLei Zhang
Aug 28, 2015·The Journal of Antimicrobial Chemotherapy·Tomas DoyleUNKNOWN CORONET Study Group
Nov 8, 2015·The Journal of Antimicrobial Chemotherapy·Teresa Llácer DelicadoÁfrica Holguín
Apr 1, 2016·The Journal of Antimicrobial Chemotherapy·Bluma G BrennerMark A Wainberg
Sep 21, 2016·Antimicrobial Agents and Chemotherapy·Manuel TsiangHaolun Jin
Apr 5, 2017·AIDS·Katherine J LepikRolando Barrios
Jul 22, 2017·The Lancet. HIV·Catherine OrrellUNKNOWN ARIA study team
Sep 5, 2017·Lancet·Joel GallantErin Quirk
Sep 5, 2017·Lancet·Paul E SaxErin Quirk
Nov 7, 2017·The Lancet. HIV·Ingeborg WijtingBart Rijnders
Dec 19, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Babafemi O TaiwoRoy M Gulick
Jun 22, 2018·The Lancet. HIV·Jean-Michel MolinaErin Quirk
Jun 22, 2018·The Lancet. HIV·Eric S DaarErin Quirk
Aug 19, 2018·Retrovirology·Maureen OliveiraUNKNOWN Montreal Primary HIV (PHI) Cohort Study Group
Citations
Aug 30, 2020·Drugs·Kimberly K ScarsiCourtney V Fletcher
Sep 16, 2020·The Journal of Antimicrobial Chemotherapy·M CasadellàUNKNOWN INSTINCT Study Group
Oct 17, 2019·The Journal of Antimicrobial Chemotherapy·Philip L TzouUNKNOWN WHO HIVResNet Working Groups
Jul 24, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Rima K AcostaKirsten L White
Jul 31, 2020·The Journal of Antimicrobial Chemotherapy·Jean L MbisaAnna Maria Geretti
Feb 13, 2021·Viruses·Steven J SmithStephen H Hughes
Oct 15, 2020·JAMA : the Journal of the American Medical Association·Michael S SaagPaul A Volberding
Mar 10, 2021·Infectious Diseases and Therapy·Franco MaggioloJoel Gallant
Apr 22, 2021·The Journal of Antimicrobial Chemotherapy·Rima K AcostaKirsten L White